Michael McElhaugh
Chief Executive Officer chez ARBUTUS BIOPHARMA CORPORATION
Fortune : 4 M $ au 31/03/2024
Profil
Michael J.
McElhaugh was the founder of Arbutus Biopharma, Inc. (founded in 2012) where he held the title of Chief Operating Officer.
He is currently the President, Chief Executive Officer, COO & Director at Arbutus Biopharma Corp.
(since 2014) and the President & Chief Executive Officer at Arbutus Biopharma, Inc. (since 2024).
In his former positions, he was the Director-Hepatitis C Worldwide Commercialization at Bristol Myers Squibb Co. and the Director-Business Development at Pharmasset, Inc. (from 2008 to 2012).
Mr. McElhaugh has a graduate degree from Thomas Jefferson University, an undergraduate degree from St. Joseph's University, and an MBA from Johnson Graduate School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/02/2024 | 1 504 793 ( 0,84% ) | 4 M $ | 31/03/2024 |
Postes actifs de Michael McElhaugh
| Sociétés | Poste | Début |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Chief Executive Officer | 01/01/2024 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Executive Officer | 01/01/2024 |
Anciens postes connus de Michael McElhaugh
| Sociétés | Poste | Fin |
|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/03/2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Founder | - |
Formation de Michael McElhaugh
| Thomas Jefferson University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
